Kiadis Pharma and Sanofi to unlock power of natural killer c...

Sanofi has struck an exclusive rights deal with Dutch biotech Kiadis focused on combining modified natural killer cells with the French pharma’s blood cancer antibody Sarcl

Poseida Therapeutics aims for $115m stock market launch to f...

California biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last week, seeking $115 million in funding for projects including a CAR

Sanofi's multiple myeloma drug approved in EU

Sanofi’s new multiple myeloma drug Sarclisa (isatuximab) has been approved in the EU for relapsed/refractory disease, taking on Johnson & Johnson’s well-established blockbuster Darzalex

Competition heats up in BCMA CAR-T as J&J, BMS update myelom...

Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough competition from a rival Johnson & Johnson drug, accord

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

J&J defends Darzalex with FDA approval for faster dosing